Daiichi Sankyo : Expiration of Marketing Alliance Agreement for TENELIA® Tablets, TENELIA® OD Tablets and CANAGLU® Tablets(405KB

March 4, 2024 Expiration of Marketing Alliance Agreement for TENELIA® Tablets, TENELIA® OD Tablets and CANAGLU® Tablets Mitsubishi Tanabe Pharma Corporation (Head Office: Chuo-ku, Osaka; Representative Director: Akihiro Tsujimura; hereinafter, "Mitsubishi Tanabe Pharma") and Daiichi Sankyo Company, Limited (Head Office: Chuo-ku, Tokyo; Representative Director, President: Hiroyuki Okuzawa; [...]

This is an abstract of the document. To keep reading, click here and get access to the original version.